These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Contrast-enhanced MRI predicts local recurrence of osteoid osteoma after radiofrequency ablation.
    Author: Mahnken AH, Bruners P, Delbrück H, Günther RW, Plumhans C.
    Journal: J Med Imaging Radiat Oncol; 2012 Dec; 56(6):617-21. PubMed ID: 23210580.
    Abstract:
    INTRODUCTION: Osteoid osteoma is a painful benign tumour, which is commonly treated by radiofrequency ablation (RFA). The goal of this study is to assess the value of contrast-enhanced magnetic resonance imaging (MRI) for predicting clinical success after RFA of osteoid osteoma. METHODS: Twenty consecutive patients (14 male, 6 female; mean age 23.3 ± 13.4 years) suffering from osteoid osteoma underwent unenhanced and contrast-enhanced T1-weighted MRI the day after RFA. Post-interventional contrast enhancement of the nidus was analyzed by comparing signal-to-noise ratios (SNR) of the nidus before and after contrast administration. The SNR between pre- and post-contrast scans was computed. RESULTS: There were no significant differences in SNR between pre- and post-contrast scans in the area of ablation (P = 0.1583), while the SNR exceeded one in four patients, indicating residual contrast enhancement. In three of these patients clinical symptoms recurred, requiring re-ablation, while one patient remained free from symptoms during follow-up. In patients with a pre- and post-contrast SNR of ≤ 1.18 no local recurrence was observed. CONCLUSIONS: Contrast enhancement on T1-weighted MRI imaging seems to be predictive of clinically unsuccessful RFA in osteoid osteoma. Patients with a SNR increase of ≥ 20% after contrast administration might be considered for re-ablation to avoid symptomatic tumour recurrence.
    [Abstract] [Full Text] [Related] [New Search]